Brief: SSY Group Says Baloxavir Marboxil Obtains Registration Approval In China From NMPA As Bulk Drug
13/07/2026 10:12
BRIEF-SSY Group Says Baloxavir Marboxil Obtains Registration Approval In China From NMPA As Bulk Drug July 13 (Reuters) - SSY Group Ltd 2005.HK:
BALOXAVIR MARBOXIL OBTAINS REGISTRATION APPROVAL IN CHINA AS BULK DRUG
OBTAINED APPROVAL FROM CHINA'S NMPA
Further company coverage: 2005.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on SSY
See all newsBrief: SSY Group Receives NMPA China Approval For Sodium Cromoglicate Eye Drops 2%
Brief: SSY Group Obtains NMPA Approval For Nimodipine Oral Solution
Brief: SSY Group Appoints Wu Heng Yao As Executive Director
Brief: SSY Group Says Ziprasidone Mesilate Receives Registration Approval In China
Hong Kong's SSY Group H1 profit rises on infusion solutions growth